xPedite: A Study to Expedite DIPG and DMG Research

This study, called xPedite, is an urgent research effort to speed up progress against DIPG and DMG — diffuse intrinsic pontine glioma and diffuse midline glioma — two devastating types of brain tumors that mainly affect children but can occur at any age. The study collects clinical data and biological samples to advance research. **You may be eligible if...** - You have a diagnosis of diffuse midline glioma (including DIPG) based on the WHO 2021 criteria, confirmed by pathology or by imaging showing a high-grade glioma in the brainstem, thalamus, or other midline brain structure - Patients of any performance status, health condition, or disease severity may be eligible - A patient's legal representative can consent on behalf of those who cannot consent themselves **You may NOT be eligible if...** - Your tumor does not meet the diagnostic criteria for diffuse midline glioma or DIPG - Neither you nor a legal representative is able to consent Talk to your doctor to see if this trial is right for you.